| US20020131908A1 (en)* | 2000-01-13 | 2002-09-19 | George Benda | Selective release apparatus for fluids |
| ATE508738T1 (en)* | 2001-01-12 | 2011-05-15 | Sun Pharma Advanced Res Co Ltd | SYSTEM FOR THE DISTANCED DELIVERY OF MEDICINAL PRODUCTS |
| KR200249057Y1 (en)* | 2001-03-22 | 2001-10-19 | 김진환 | Sewage backflow integrated into the lid and base. Odor Prevention Device |
| DK1377276T3 (en)* | 2001-04-10 | 2012-01-02 | Sun Pharma Advanced Res Co Ltd | Calculation of pulse-release composition |
| ES2501142T3 (en)* | 2001-07-12 | 2014-10-01 | Given Imaging Ltd. | Device to examine an internal body cavity |
| US7585283B2 (en)* | 2001-07-12 | 2009-09-08 | Given Imaging Ltd. | Device and method for examining a body lumen |
| US20030175346A1 (en)* | 2002-02-01 | 2003-09-18 | Anne Billotte | Osmotic delivery system |
| GB0203296D0 (en)* | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| ITMI20020515A1 (en)* | 2002-03-12 | 2003-09-12 | Jagotec Ag | SYSTEM FOR THE CONTROLLED RELEASE OF ONE OR MORE ACTIVE INGREDIENTS |
| ITMI20020514A1 (en)* | 2002-03-12 | 2003-09-12 | Jagotec Ag | THERAPEUTIC SYSTEM FOR THE CONTROLLED RELEASE OF ONE OR MORE ACTIVE PRINCIPLES |
| US8523788B2 (en)* | 2002-07-11 | 2013-09-03 | Given Imaging Ltd. | Device, system and method for examining a body lumen |
| US20050208132A1 (en)* | 2002-07-29 | 2005-09-22 | Gayatri Sathyan | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US9060941B2 (en)* | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US8293799B2 (en)* | 2003-12-29 | 2012-10-23 | Osmotica Keresleedelmo és Szolgáltató KFT | Osmotic device containing a venlafaxine salt and a salt having an ion in common |
| US20060210633A1 (en)* | 2003-04-03 | 2006-09-21 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
| JP4790597B2 (en) | 2003-04-24 | 2011-10-12 | ヤゴテック アーゲー | Delayed release tablets with defined core geometry |
| EP1615626B1 (en)* | 2003-04-24 | 2009-10-14 | Jagotec Ag | Tablet with coloured core |
| US20060177507A1 (en)* | 2003-05-22 | 2006-08-10 | Joaquina Faour | Controlled release device containing lercanidipine |
| US8029822B2 (en)* | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
| UY28326A1 (en)* | 2003-05-22 | 2004-06-30 | Osmotica Argentina S A | BREAKDOWN DEVICE CONTROLLED WITH A PREFORMED PASSAGE |
| US20050136108A1 (en)* | 2003-08-22 | 2005-06-23 | Yam Noymi V. | Stepwise delivery of topiramate over prolonged period of time |
| US7611728B2 (en)* | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
| DE10351448A1 (en)* | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Flavor-containing drug formulations with improved pharmaceutical properties |
| AU2004296404A1 (en)* | 2003-12-09 | 2005-06-23 | Spherics, Inc. | Bioadhesive polymers with catechol functionality |
| SE0401031D0 (en)* | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| US8574626B2 (en) | 2004-12-03 | 2013-11-05 | Osmotica Kereskedelmi és Szolgáltató KFT | Osmotic device containing amantadine and an osmotic salt |
| US8252331B2 (en)* | 2004-12-03 | 2012-08-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Osmotic device containing amantadine and an osmotic salt |
| AR053986A1 (en) | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | OSMOTIC DEVICE CONTAINING AMANTADINE AND AN OSMOTIC SALT |
| US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
| US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
| US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
| EP3827747A1 (en) | 2005-04-28 | 2021-06-02 | Otsuka Pharmaceutical Co., Ltd. | Pharma-informatics system |
| US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
| EP2502621A1 (en)* | 2005-06-27 | 2012-09-26 | Valeant International (Barbados) SRL | Crystalline forms of bupropion HBr |
| CN101291652A (en)* | 2005-06-29 | 2008-10-22 | 阿尔扎公司 | Semipermeable compositions providing reduced drying time for osmotic dosage forms |
| JP2009544338A (en) | 2006-05-02 | 2009-12-17 | プロテウス バイオメディカル インコーポレイテッド | Treatment regimen customized to the patient |
| US7772390B1 (en) | 2006-07-18 | 2010-08-10 | The Regents Of The University Of California | Lipid mediated nucleic acid synthesis |
| HRP20130148T4 (en) | 2006-08-03 | 2016-10-07 | Horizon Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
| SG175681A1 (en) | 2006-10-25 | 2011-11-28 | Proteus Biomedical Inc | Controlled activation ingestible identifier |
| US8718193B2 (en) | 2006-11-20 | 2014-05-06 | Proteus Digital Health, Inc. | Active signal processing personal health signal receivers |
| CN101686800A (en) | 2007-02-01 | 2010-03-31 | 普罗秋斯生物医学公司 | Ingestible Event Marker System |
| US8956288B2 (en) | 2007-02-14 | 2015-02-17 | Proteus Digital Health, Inc. | In-body power source having high surface area electrode |
| EP2124725A1 (en) | 2007-03-09 | 2009-12-02 | Proteus Biomedical, Inc. | In-body device having a multi-directional transmitter |
| EP2063771A1 (en) | 2007-03-09 | 2009-06-03 | Proteus Biomedical, Inc. | In-body device having a deployable antenna |
| US8115618B2 (en) | 2007-05-24 | 2012-02-14 | Proteus Biomedical, Inc. | RFID antenna for in-body device |
| BRPI0812918A2 (en)* | 2007-06-21 | 2014-12-09 | Swelltec Ltd | APPLIANCE AND METHOD WITH HYDROCARBILITY AND WATER DILATABLE BODY |
| GB0711979D0 (en)* | 2007-06-21 | 2007-08-01 | Swelltec Ltd | Method and apparatus |
| US20090004281A1 (en)* | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
| US8637080B2 (en)* | 2007-06-28 | 2014-01-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Rupturing controlled release device comprising a subcoat |
| DK2192946T3 (en) | 2007-09-25 | 2022-11-21 | Otsuka Pharma Co Ltd | In-body device with virtual dipole signal amplification |
| CN104376659B (en) | 2008-03-05 | 2019-10-25 | 普罗透斯数字保健公司 | The ingestible event flag of multi-modal communications and system, and the method using it |
| US20090312627A1 (en)* | 2008-06-16 | 2009-12-17 | Matott Laura A | Radio-labeled ingestible capsule |
| AU2009268827B2 (en) | 2008-07-08 | 2013-10-24 | Proteus Digital Health, Inc. | Ingestible event marker data framework |
| WO2010015840A1 (en)* | 2008-08-08 | 2010-02-11 | Cipla Limited | Osmotic delivery device with modified release |
| MY154217A (en) | 2008-08-13 | 2015-05-15 | Proteus Digital Health Inc | Ingestible circuitry |
| US20100069821A1 (en)* | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-sites final dosage form |
| US20100068254A1 (en)* | 2008-09-16 | 2010-03-18 | Mahalaxmi Gita Bangera | Modifying a medicament availability state of a final dosage form |
| US20100068153A1 (en)* | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo activatable final dosage form |
| US20100068152A1 (en)* | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable particle or polymeric based final dosage form |
| US20100069887A1 (en)* | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multiple chamber ex vivo adjustable-release final dosage form |
| US20100068233A1 (en)* | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Modifiable dosage form |
| US8753677B2 (en)* | 2008-09-16 | 2014-06-17 | The Invention Science Fund I, Llc | Ex vivo modifiable multiple medicament final dosage form |
| US20100068235A1 (en)* | 2008-09-16 | 2010-03-18 | Searete LLC, a limited liability corporation of Deleware | Individualizable dosage form |
| US20100068275A1 (en)* | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Personalizable dosage form |
| KR20110103446A (en) | 2009-01-06 | 2011-09-20 | 프로테우스 바이오메디컬, 인코포레이티드 | Intake-Related Biofeedback and Individualized Medical Treatment Methods and Systems |
| SG172847A1 (en) | 2009-01-06 | 2011-08-29 | Proteus Biomedical Inc | Pharmaceutical dosages delivery system |
| WO2010084188A1 (en)* | 2009-01-26 | 2010-07-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
| NZ582836A (en)* | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
| WO2010111403A2 (en) | 2009-03-25 | 2010-09-30 | Proteus Biomedical, Inc. | Probablistic pharmacokinetic and pharmacodynamic modeling |
| EP3906845A1 (en) | 2009-04-28 | 2021-11-10 | Otsuka Pharmaceutical Co., Ltd. | Highly reliable ingestible event markers |
| EP2432458A4 (en)* | 2009-05-12 | 2014-02-12 | Proteus Digital Health Inc | Ingestible event markers comprising an ingestible component |
| TWI517050B (en) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | System for supply chain management |
| US8945010B2 (en) | 2009-12-23 | 2015-02-03 | Covidien Lp | Method of evaluating constipation using an ingestible capsule |
| WO2011127252A2 (en) | 2010-04-07 | 2011-10-13 | Proteus Biomedical, Inc. | Miniature ingestible device |
| TWI557672B (en) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device |
| JP2014504902A (en) | 2010-11-22 | 2014-02-27 | プロテウス デジタル ヘルス， インコーポレイテッド | Ingestible device with medicinal product |
| US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| PH12014500174A1 (en) | 2011-07-21 | 2024-02-12 | Proteus Digital Health Inc | Mobile communication device, system, and method |
| US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
| EP2874886B1 (en) | 2012-07-23 | 2023-12-20 | Otsuka Pharmaceutical Co., Ltd. | Techniques for manufacturing ingestible event markers comprising an ingestible component |
| CN102871982B (en)* | 2012-10-16 | 2014-09-10 | 中国科学院上海药物研究所 | Medicine osmotic pump preparation |
| AU2013331417B2 (en) | 2012-10-18 | 2016-06-02 | Proteus Digital Health, Inc. | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
| US11149123B2 (en) | 2013-01-29 | 2021-10-19 | Otsuka Pharmaceutical Co., Ltd. | Highly-swellable polymeric films and compositions comprising the same |
| WO2014144738A1 (en) | 2013-03-15 | 2014-09-18 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
| EP3005281A4 (en) | 2013-06-04 | 2017-06-28 | Proteus Digital Health, Inc. | System, apparatus and methods for data collection and assessing outcomes |
| US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
| WO2015038854A1 (en)* | 2013-09-13 | 2015-03-19 | R.P. Scherer Technologies, Llc | Encased-pellet tablets |
| US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
| US20150307754A1 (en)* | 2014-04-28 | 2015-10-29 | Celanese Acetate Llc | Adhesives that include highly-plasticized cellulose esters and methods and articles relating thereto |
| US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
| US10987328B2 (en) | 2015-02-20 | 2021-04-27 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
| WO2016132218A1 (en) | 2015-02-20 | 2016-08-25 | Osmotica Kereskedelmi Es Szolgaltato Kft | Method of administering r-baclofen in an extended release dosage form |
| US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
| US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
| KR20210018961A (en) | 2016-07-22 | 2021-02-18 | 프로테우스 디지털 헬스, 인코포레이티드 | Electromagnetic sensing and detection of ingestible event markers |
| CN109963499B (en) | 2016-10-26 | 2022-02-25 | 大冢制药株式会社 | Method for manufacturing capsules with ingestible event markers |
| US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
| US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |